COCP
Cocrystal Pharma, Inc.
Biotechnology · Healthcare · United States
1.00
close · 2026-10-30
value
1
cheaper than peers1
quality
2
stronger fundamentals2
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, latest year | -42.8% | 21 |
| price to sales | 58.08× | 21 |
| price to book | 13.09× | 16 |
| cash flow yield, 2 years ago | -77.1% | 12 |
| cash flow yield, 3 years ago | -112.2% | 12 |
| earnings yield, latest year | -78.4% | 11 |
| earnings yield, 2 years ago | -187.9% | 11 |
| cash flow yield, 1 year ago | -86.0% | 10 |
| earnings yield, 1 year ago | -172.9% | 9 |
| earnings yield, 3 years ago | -479.4% | 4 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 128.4% | 19 |
| return on equity | -311.7% | 8 |
| operating margin | -3032.4% | 8 |
3 of 4 measures available
Facts
| market cap | $19M |
| free cash flow | -$4.3M |
| employees | 10 |
| first trade | 2012-02-22 |
| next earnings | not reported |
| fundamentals updated | 2026-08-17 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.78 | -1.72 | -1.87 | -4.77 |
| free cash flow | -$8.2M | -$16.5M | -$14.8M | -$21.5M |
| net income | -$8.8M | -$17.5M | -$18.0M | -$38.8M |
| revenue | $0 | $0 | $0 | $0 |
| unusual items | $54,000 | -$163,000 | $2.5M | -$20.7M |